High-throughput screening identifies inhibitors of DUX4-induced myoblast toxicity.

PubWeight™: 0.84‹?›

🔗 View Article (PMC 3914678)

Published in Skelet Muscle on February 01, 2014

Authors

Darko Bosnakovski1,2,3, Si Ho Choi1,2, Jessica M Strasser4, Erik A Toso1,2, Michael A Walters4, Michael Kyba1,2

Author Affiliations

1: Lillehei Heart Institute, 312 Church St. SE, Minneapolis, MN 55455, USA.
2: Department of Pediatrics, University of Minnesota, Nils Hasselmo Hall, 312 Church St. S.E, Minneapolis, MN 55455, USA.
3: Present Address: Faculty of Medical Sciences, University Goce Delčev - Štip, Krste Misirkov b.b, 2000 Štip, R. Macedonia.
4: Institute for Therapeutics Discovery and Development, University of Minnesota, 717 Delaware St. SE, Minneapolis, MN 55455, USA.

Articles cited by this

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res (2008) 9.65

New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem (2010) 6.54

Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet (1992) 5.12

A unifying genetic model for facioscapulohumeral muscular dystrophy. Science (2010) 4.87

FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet (1993) 4.21

Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet (2003) 3.60

Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell (2002) 3.56

DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc Natl Acad Sci U S A (2007) 3.32

Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene (1999) 3.00

Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet (2009) 2.90

The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscul Disord (2007) 2.85

Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum Mutat (2009) 2.84

Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet (2012) 2.82

An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO J (2008) 2.74

Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy. Am J Hum Genet (2007) 2.54

Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Hum Mol Genet (2003) 2.50

Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain (2009) 2.38

Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy. Am J Hum Genet (2004) 1.72

Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress. Neuromuscul Disord (2003) 1.56

DUX4c, an FSHD candidate gene, interferes with myogenic regulators and abolishes myoblast differentiation. Exp Neurol (2008) 1.48

Biphasic myopathic phenotype of mouse DUX, an ORF within conserved FSHD-related repeats. PLoS One (2009) 1.25

Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with oxidative stress and mitochondrial dysfunction. Free Radic Biol Med (2012) 0.99